17:39:18 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


Vibrosense Dynamics är verksamma inom medicinteknik. Bolaget utvecklar produkter och tjänster för diagnostikstöd vid nervskador i händer och fötter. Produkterna mäter och kvantifierar förmågan att känna vibrationer i huden, och används av vårdgivare för att kunna anpassa behandlingen eller sätta in förebyggande åtgärder vid potentiella nervskador. Bolagets kunder är diabetesmottagningar, sjukhus, vårdcentraler och forskningsinstitut.


2022-08-30 Bokslutskommuniké 2022
2022-05-04 Kvartalsrapport 2022-Q3
2022-02-11 Kvartalsrapport 2022-Q2
2021-10-22 Kvartalsrapport 2022-Q1
2021-10-06 Ordinarie utdelning VSD B 0.00 SEK
2021-10-05 Årsstämma 2022
2021-08-30 Bokslutskommuniké 2021
2021-05-12 Kvartalsrapport 2021-Q3
2021-02-12 Kvartalsrapport 2021-Q2
2020-11-12 Kvartalsrapport 2021-Q1
2020-10-08 Ordinarie utdelning VSD B 0.00 SEK
2020-10-07 Årsstämma 2021
2020-08-31 Bokslutskommuniké 2020
2020-05-15 Kvartalsrapport 2020-Q3
2020-05-04 Extra Bolagsstämma 2020
2020-02-14 Kvartalsrapport 2020-Q2
2019-11-01 Kvartalsrapport 2020-Q1
2019-10-10 Ordinarie utdelning VSD B 0.00 SEK
2019-10-09 Årsstämma 2020
2019-08-30 Bokslutskommuniké 2019
2019-05-16 Kvartalsrapport 2019-Q3
2019-02-14 Kvartalsrapport 2019-Q2
2018-10-30 Kvartalsrapport 2019-Q1
2018-10-17 Ordinarie utdelning VSD B 0.00 SEK
2018-10-16 Årsstämma 2019
2018-08-31 Bokslutskommuniké 2018
2018-05-16 Kvartalsrapport 2018-Q3
2018-02-14 Kvartalsrapport 2018-Q2
2017-10-30 Kvartalsrapport 2018-Q1
2017-10-02 Ordinarie utdelning VSD B 0.00 SEK
2017-09-29 Årsstämma 2018
2017-08-30 Bokslutskommuniké 2017
2017-05-22 Kvartalsrapport 2017-Q3
2017-02-20 Kvartalsrapport 2017-Q2
2017-01-25 Extra Bolagsstämma 2017
2016-11-07 Kvartalsrapport 2017-Q1
2016-08-29 Ordinarie utdelning VSD B 0.00 SEK
2016-08-26 Bokslutskommuniké 2016
2016-05-26 Kvartalsrapport 2016-Q3
2016-02-25 Kvartalsrapport 2016-Q2
2015-11-26 Kvartalsrapport 2016-Q1
2015-08-27 Bokslutskommuniké 2015
2020-03-26 08:15:00

VibroSense Dynamics AB (VibroSense) adds a new application to its product VibroSense Meter® II, which provides support for Diabetes Foot Screening. The new application is a result of 5 years of clinical studies involving adult patients with type 1 diabetes and is expected to be available for commercial launch in the fall 2020.

The screening function of VibroSense Meter® II within HAVS (vibration damage), was launched in the fall 2019 and is an application to detect early nerve damage in hands caused by vibrating tools. Research at Skåne University Hospital have shown that the method can also favorably be used to early detect nerve impairments of feet on people with type 1 diabetes. The result of a Diabetes Screening is reported in three gradings: Normal, Suspected, or Significant deviation in relation to a reference group, consisting of 1,100 healthy individuals aged 8 to 80 years. Suspected or Significant deviation indicates that possible nerve damage may exist. The screening method gives the healthcare sector access to a new tool that offers reliable and repetitive measurement to detect early nerve damage caused by diabetes.


- The launch of the new application Diabetes Screening, is part of VibroSense's long-term strategy to add new applications to the product, as soon as new clinical data becomes available from the company's research partners. After completing a 5-year prospective study involving adults with type 1 diabetes, VibroSense has now compiled clinical data that is the basis of the new screening module. The screening takes less than 10 minutes and gives health care professionals in diabetes a reliable result, saving a lot of time. We are very pleased to offer a new and effective instrument, as a complement to today's existing tools, many of which are over 50 years old, says Hans Wallin, CEO VibroSense Dynamics AB.


Contact VibroSense Dynamics AB

Hans Wallin, CEO VibroSense Dynamics AB,
Phone: +46 40 88 026
E-mail: info@vibrosense.com




About VibroSense Dynamics AB (publ)

VibroSense Dynamics AB (public) manufactures and develops efficient systems to support early detection and diagnosis of sensory neuropathy, i.e. disease of large nerve fibres and nerve trunks in e.g. legs and arms. Our vision is that the VibroSense Meter shall be the golden standard instrument for neurological examinations to assess sensory neuropathy and help to improve life conditions for patients having a risk of getting nerve injuries.